Are you at The CheckPoints at the Marriott Marquis tonight? Stop by our photo booth, sponsored by @PyxisOncology, and get a photo of your #SITC23 experience!
Vigeo Therapeutics is excited to announce our inclusion in the AGILE Ph2-3 registrational study for glioblastoma with @GCAResearch#CD47#GBM#TME#oncology https://t.co/dJwnmQu6ZM
Vigeo Therapeutics is excited to be joining the AGILE Phase 2-3 study for patients with newly diagnosed and recurrent GBM #CD36#CD47#oncology https://t.co/QxG7JlSlK4
Thank you for the hard work by the @vigeotx team to bring this poster of our GBM data to #SNO2021 meeting in Boston last week #CD47#CD36#immunooncology https://t.co/B66VGAyK8x
This week we are presenting new data at SNO’s annual meeting from our Ph1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma. More details here: https://t.co/9Z3ODvjDqW
@NeuroOnc#CD47#CD46#ImmunoOncology
This week we are presenting new data at SITC's annual meeting from our Ph 1/2 study evaluating the single-agent activity of VT1021 in subjects with pancreatic cancer and recurrent glioblastoma. More details here:https://t.co/kOWLlZj4Ku
@sitcancer#CD47#CD46#ImmunoOncology
Next month we will be presenting new Phase 1/2 data from our pancreatic cancer expansion study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting. More details here: https://t.co/s5mDq9Qm6x
@sitcancer#CD47#CD46#ImmunoOncology
Read the latest clinical update on VT1021, a first-in-class, dual-modulating compound that blocks the #CD47 immune checkpoint and activates #CD36
and hear from our new CEO, Jim Mahoney. See full press release here: https://t.co/f5wgoxlttq
#ImmunoOncology